All In Biotech

NDA 022332 · Eli Lilly CO

Adcirca

Tadalafil · Oral · Phosphodiesterase 5 Inhibitor

Orphan

Last checked: Nov 20, 2026Latest source record: Sep 15, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

May 22, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

259

70 Phase 3, 23 recruiting

FAERS reports

76,234

51,425 serious, 9,971 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 15, 2025.

ADCIRCA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II – III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%). ( 1.1 ) 1.1 Pulmonary Arterial Hypertension ADCIRCA ® is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II – III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%).

Mechanism: Tadalafil is an inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP). Pulmonary arterial hypertension is associated with impaired release of nitric oxide by the vascular endothelium and consequent reduction of cGMP concentrations in the pulmonary vascular smooth muscle. PDE5 is the predominant phosphodiesterase in the pulmonary vasculature. Inhibition of PDE5 by tadalafil increases the concentrations of cGMP resulting in relaxation of pulmonary vascular smooth muscle cells and vasodilation of the pulmonary vascular...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 22, 2009 Original approval · Type 6 - New Indication (no longer used) LetterLabelReview
1 products under this application
  • ADCIRCA · TADALAFIL 20MG · TABLET, ORAL · Prescription · TE AB2

Clinical trials

Interventional ClinicalTrials.gov studies with "Tadalafil" as an intervention, any sponsor and status, largest first.

All 259 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea11,617
  • headache9,611
  • diarrhoea7,571
  • nausea6,235
  • death5,473
  • fatigue5,330
  • dizziness4,740
  • cough4,315
  • pneumonia4,078
  • malaise3,537
  • vomiting3,308
  • fluid retention3,143

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200424
200513
200615
200737
200826
200949
2010206
2011787
20121,251
20131,755
20146,366
20156,085
20165,849
20175,783
20186,736
20195,852
20204,946
20214,657
20224,940
20235,545
20245,552
20255,853
20263,907

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Nov 5, 2026

    Adcirca, Tablet, 20 mg (NDC 66302-467-60). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Adcirca (Tadalafil)

2024 spending

$23.8M

Beneficiaries

680

5,153 claims

Per beneficiary

$35,037

$67.26 per unit

View as table
YearSpending
2020$55,942,543
2021$43,282,513
2022$33,526,807
2023$29,259,353
2024$23,825,305

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 562 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.